Indaptus Therapeutics Net Income
| INDP Stock | USD 2.01 0.19 8.64% |
As of the 3rd of February, Indaptus Therapeutics retains the Market Risk Adjusted Performance of (0.16), standard deviation of 8.37, and Risk Adjusted Performance of (0.03). Indaptus Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Indaptus Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Indaptus Therapeutics' valuation are summarized below:There are currently one hundred twenty fundamental trends for Indaptus Therapeutics that can be evaluated and compared over time across competitors. Investors and active traders are advised to confirm Indaptus Therapeutics' regular fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/03/2026, Market Cap is likely to drop to about 241 M. In addition to that, Enterprise Value is likely to drop to about 234.8 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -13.5 M | -14.2 M | |
| Net Loss | -12.9 M | -12.2 M | |
| Net Loss | -13.5 M | -14.2 M | |
| Net Loss | (1.85) | (1.94) | |
| Net Income Per E B T | 0.91 | 0.81 |
Indaptus | Net Income | Build AI portfolio with Indaptus Stock |
Evaluating Indaptus Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Indaptus Therapeutics's fundamental strength.
Latest Indaptus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Indaptus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Indaptus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Indaptus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Indaptus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Indaptus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.02 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Indaptus Net Income Regression Statistics
| Arithmetic Mean | (14,899,009) | |
| Coefficient Of Variation | (88.00) | |
| Mean Deviation | 8,941,348 | |
| Median | (13,362,000) | |
| Standard Deviation | 13,111,387 | |
| Sample Variance | 171.9T | |
| Range | 44M | |
| R-Value | (0.24) | |
| Mean Square Error | 172.5T | |
| R-Squared | 0.06 | |
| Significance | 0.35 | |
| Slope | (632,798) | |
| Total Sum of Squares | 2750.5T |
Indaptus Net Income History
Other Fundumenentals of Indaptus Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Indaptus Therapeutics Net Income component correlations
Indaptus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as Net Income. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Indaptus have expansion opportunities? Factors like these will boost the valuation of Indaptus Therapeutics. Market participants price Indaptus higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Indaptus Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Indaptus Therapeutics requires distinguishing between market price and book value, where the latter reflects Indaptus's accounting equity. The concept of intrinsic value—what Indaptus Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Indaptus Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Indaptus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Indaptus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Indaptus Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Indaptus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Indaptus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Indaptus Therapeutics.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Indaptus Therapeutics on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Indaptus Therapeutics or generate 0.0% return on investment in Indaptus Therapeutics over 90 days. Indaptus Therapeutics is related to or competes with Biomotion Sciences, Revelation Biosciences, Psyence Biomedical, GT Biopharma, Avenue Therapeutics, Protagenic Therapeutics, and Lipella Pharmaceuticals. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunothe... More
Indaptus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Indaptus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Indaptus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 51.64 | |||
| Value At Risk | (12.56) | |||
| Potential Upside | 13.58 |
Indaptus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Indaptus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Indaptus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Indaptus Therapeutics historical prices to predict the future Indaptus Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.17) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Indaptus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Indaptus Therapeutics February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 5.93 | |||
| Coefficient Of Variation | (1,716) | |||
| Standard Deviation | 8.37 | |||
| Variance | 70.09 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 51.64 | |||
| Value At Risk | (12.56) | |||
| Potential Upside | 13.58 | |||
| Skewness | 1.39 | |||
| Kurtosis | 4.75 |
Indaptus Therapeutics Backtested Returns
Indaptus Therapeutics holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of risk over the last 3 months. Indaptus Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Indaptus Therapeutics' Standard Deviation of 8.37, risk adjusted performance of (0.03), and Market Risk Adjusted Performance of (0.16) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.91, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Indaptus Therapeutics will likely underperform. At this point, Indaptus Therapeutics has a negative expected return of -0.076%. Please make sure to check out Indaptus Therapeutics' jensen alpha, as well as the relationship between the kurtosis and period momentum indicator , to decide if Indaptus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.5 |
Modest reverse predictability
Indaptus Therapeutics has modest reverse predictability. Overlapping area represents the amount of predictability between Indaptus Therapeutics time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Indaptus Therapeutics price movement. The serial correlation of -0.5 indicates that about 50.0% of current Indaptus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.5 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.14 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Indaptus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Indaptus Therapeutics reported net income of (15.02 Million). This is 104.4% lower than that of the Biotechnology sector and 121.45% lower than that of the Health Care industry. The net income for all United States stocks is 102.63% higher than that of the company.
Indaptus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in net income category among its peers.
Indaptus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Indaptus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Indaptus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Indaptus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Indaptus Therapeutics' value.| Shares | Vivaldi Capital Management, Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Virtu Financial Llc | 2025-06-30 | 0.0 | Investment House Llc | 2025-06-30 | 0.0 | Strategy Asset Managers Llc | 2025-06-30 | 0.0 | Two Sigma Securities, Llc | 2025-03-31 | 0.0 | Sbi Securities Co Ltd | 2025-06-30 | 156 | Tower Research Capital Llc | 2025-06-30 | 108 |
Indaptus Fundamentals
| Return On Equity | -3.18 | ||||
| Return On Asset | -1.31 | ||||
| Current Valuation | (906.26 K) | ||||
| Shares Outstanding | 2.24 M | ||||
| Shares Owned By Insiders | 36.05 % | ||||
| Shares Owned By Institutions | 4.48 % | ||||
| Number Of Shares Shorted | 68.03 K | ||||
| Price To Book | 1.07 X | ||||
| EBITDA | (15.37 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 2.81 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (29.03) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 4.93 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 7.34 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Indaptus Stock
| 0.45 | XNCR | Xencor Inc | PairCorr |
| 0.39 | GANX | Gain Therapeutics | PairCorr |
| 0.35 | KURA | Kura Oncology | PairCorr |
| 0.31 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.